Skip to main content

Market Overview

BeyondSpring Files US-China Application For Plinabulin G-CSF Treatment In Chemo-Induced Neutropenia

Share:
BeyondSpring Files US-China Application For Plinabulin G-CSF Treatment In Chemo-Induced Neutropenia
  • BeyondSpring Inc (NASDAQ: BYSIhas submitted marketing applications in the U.S. and China seeking approval for plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN).
  • Neutropenia is a condition wherein a person has a low level of neutrophils, a white blood cell that helps the body fight infection.
  • The submission is based on data from PROTECTIVE-2 Phase 3 study, which showed that plinabulin combined with pegfilgrastim demonstrated superior CIN prevention benefit compared to pegfilgrastim alone.
  • The study met the primary endpoint, with a statistically significant improvement in the rate of prevention of grade 4 neutropenia (improved from 13.6% to 31.5%).
  • Price Action: BYSI shares are up 4.1% higher at $11.07 in the premarket trading on the last check Thursday.
 

Related Articles (BYSI)

View Comments and Join the Discussion!

Posted-In: NeutropeniaBiotech News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com